


### AMENDMENTS TO THE CLAIMS

1. (Previously Presented) An immunological test kit comprising an immunologically reactive substance connected to an immunologically invisible carrier unit, said immunologically invisible carrier unit comprising a polyethylene glycol copolymer of the structure of:



wherein n represents the number of units connected in a chain, and R the immunologically reactive substance.

2. (Previously Presented) The test kit of claim 1, wherein said immunological test kit is an ELISA kit.


3. (Previously Presented) The test kit of claim 1, wherein said immunological test kit is a capillary immuno-chromatography kit or a column immuno-chromatography kit.

4. (Cancelled)

5. (Previously Presented) The test kit of claim 1 wherein the immunologically reactive substance comprises an epitope.

6. (Previously Presented) The test kit of claim 1 wherein the immunologically reactive substance comprises an antibody.
7. (Previously Presented) The test kit of claim 1, wherein the immunologically reactive substance comprises an antigen.
8. (Cancelled)
9. (Previously Presented) The test kit of claim 1, wherein the carrier consists of one to eight units.
10. (Previously Presented) The test kit of claim 1, wherein the carrier consists of three to eight units.
- 11-12. (Cancelled)
13. (Previously Presented) The test kit of claim 1, wherein the immunologically reactive substance comprises an amino acid sequence selected from the group consisting of: VQEGVQQEGAQQP-(beta-A)(beta-A)C; EIAAKAIGKKIHQNG-(beta-A)(beta-A)C; ISTLIKQKLDGLKNE-(beta-A)(beta-A)C; PVVAESP KKPE-(beta-A)(beta-A)C; DKKAINLDKAQQKLD-(beta-A)(beta-A)C; ITKGKSQKSLGD-(beta-A)(beta-A)C; and GMTFRAQEGAFLTG-(beta-A)(beta-A)C.
- 14-16. (Cancelled)

17. (Previously Presented) A composition of matter comprising an immunologically reactive substance connected to an immunologically invisible carrier unit, said immunologically invisible carrier unit comprising a polyethylene glycol copolymer of the structure of:



wherein n represents the number of units connected in a chain, and R is the immunologically reactive substance.

18. (Cancelled)

19. (Previously Presented) The composition of matter of claim 17, wherein the carrier consists of one to eight units.

20. (Previously Presented) The composition of matter of claim 17, wherein the carrier consists of three to eight units.

21-24. (Cancelled)

25. (Previously Presented) The composition of matter of claim 17, wherein the immunologically reactive substance comprises an amino acid sequence selected from the group consisting of:

VQEGVQQEGAQQP-(beta-A)(beta-A)C; EIAAKAIGKKIHQNNG-(beta-A)(beta-A)C;  
ISTLIKQKLDGLKNE-(beta-A)(beta-A)C; PVVAESPCKPE-(beta-A)(beta-A)C;  
DKKAINLDKAQQKLD-(beta-A)(beta-A)C; ITKGKSQKSLGD-(beta-A)(beta-A)C; and  
GMTFRAQEGAFLTG-(beta-A)(beta-A)C.

26-28. (Cancelled)

29. (Previously Presented) The test kit of claim 1, wherein each unit of the chain carries the same immunologically reactive substance.

30. (Previously Presented) The test kit of claim 1, wherein each unit of the chain optionally carries a different immunologically reactive substance.

31. (Previously Presented) The test kit of claim 1, wherein the immunologically invisible carrier unit further comprises a reporter moiety.

32. (Previously Presented) The test kit of claim 31, wherein the reporter moiety is biotin.

33. (Previously Presented) The test kit of claim 13, wherein each unit of the chain carries the same immunologically reactive substance.

34. (Previously Presented) The test kit of claim 13, wherein each unit of the chain optionally carries a different immunologically reactive substance.

35. (Previously Presented) The composition of matter of claim 17, wherein the immunologically reactive substance comprises an epitope.

36. (Previously Presented) The composition of matter of claim 17, wherein the immunologically reactive substance comprises an antibody.

37. (Previously Presented) The composition of matter of claim 17, wherein the immunologically reactive substance comprises an antigen.

38. (Previously Presented) The composition of matter of claim 17, wherein each unit of the chain carries the same immunologically reactive substance.
39. (Previously Presented) The composition of matter of claim 17, wherein each unit of the chain optionally carries a different immunologically reactive substance.
40. (Previously Presented) The composition of matter of claim 17, wherein the immunologically invisible carrier unit further comprises a reporter moiety.
41. (Previously Presented) The composition of matter of claim 40, wherein the reporter moiety is biotin.
42. (Previously Presented) The composition of matter of claim 25, wherein each unit of the chain carries the same immunologically reactive substance.
43. (Previously Presented) The composition of matter of claim 25, wherein each unit of the chain optionally carries a different immunologically reactive substance.
44. (Previously Presented) The test kit of claim 1, wherein the immunologically reactive substance comprises an isolated, purified amino acid sequence of GMTFRAQEGAFITG-(beta-A)(beta-A)C.
45. (Previously Presented) The composition of matter of claim 17, wherein the immunologically reactive substance comprises an isolated, purified amino acid sequence of GMTFRAQEGAFITG-(beta-A)(beta-A)C.
- 46-47. (Cancelled)
48. (Previously Presented) The test kit of claim 1, wherein R comprises an amino acid sequence of 11 to 16 amino acids.
49. (Previously Presented) The composition of matter of claim 17, wherein R comprises an amino acid sequence of 11 to 16 amino acids.

50. (New) The test kit of claim 13, wherein the carrier consists of one to seven units and each unit optionally carries a different immunologically reactive substance.
51. (New) The composition of matter of claim 25, wherein the carrier consists of one to seven units and each unit optionally carries a different immunologically reactive substance.